Urology
ESMO Guideline | Updated treatment recommendations for prostate cancer
6 Apr, 2023 | 13:18h | UTC
Guideline | Muscle-invasive and metastatic bladder cancer
6 Apr, 2023 | 13:19h | UTCMuscle-invasive and Metastatic Bladder Cancer – European Association of Urology (see PDF)
Consensus Paper | Treatment of sexual dysfunction after surgery for prostate cancer
22 Mar, 2023 | 13:34h | UTC
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
15 Mar, 2023 | 15:24h | UTCSummary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.
The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.
The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.
Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence
Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer
15 Mar, 2023 | 15:11h | UTC
Review | Approach to the patient with adrenal hemorrhage
15 Mar, 2023 | 15:03h | UTCApproach to the Patient With Adrenal Hemorrhage – The Journal of Clinical Endocrinology & Metabolism
Press release | New technique reduces postoperative complications in prostate cancer surgery
14 Mar, 2023 | 13:33h | UTC
RCT | Cannabidiol oil not effective for post-ureteroscopy pain control
10 Mar, 2023 | 14:34h | UTCSummary: The study evaluated the effect of cannabidiol oil on pain control and opioid usage in patients undergoing ureteroscopy with stent placement for urinary stone disease. Ninety patients were randomized 1:1 to receive either placebo or 20mg of cannabidiol oil daily for 3 days postoperatively.
Results showed no difference between CBD oil and placebo in reducing pain scores, opioid usage, or stent-related symptoms. The study suggests that despite the availability of numerous analgesic agents, stent symptoms continue to be bothersome for most patients, and further research is needed to find effective non-opioid alternatives for pain management in this setting.
Article: Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial – The Journal of Urology (free for a limited period)
Consensus Paper | Management of patients with advanced prostate cancer
7 Mar, 2023 | 13:02h | UTC
RCT | Hydrochlorothiazide is not effective for the prevention of kidney-stone recurrence
6 Mar, 2023 | 14:26h | UTCSummary:
This study aimed to assess the effectiveness of hydrochlorothiazide, a thiazide diuretic, in preventing the recurrence of calcium-containing kidney stones. The trial randomly assigned 416 patients with recurrent kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 mg once daily, or a placebo once daily, and followed them for a median of 2.9 years.
The results showed that the incidence of kidney stone recurrence did not differ significantly between the hydrochlorothiazide and placebo groups, regardless of the dose. Furthermore, patients who received hydrochlorothiazide were more likely to experience side effects such as hypokalemia, gout, new-onset diabetes mellitus, skin allergy, and a plasma creatinine level exceeding 150% of the baseline level.
Therefore, the effectiveness of hydrochlorothiazide in preventing kidney stone recurrence may be limited, and the common practice of prescribing it for these patients should be reevaluated.
Article: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence – New England Journal of Medicine (link to abstract – $ for full-text)
Video Summary: Hydrochlorothiazide and Kidney-Stone Recurrence | NEJM
Commentary: Hydrochlorothiazide and Prevention of Kidney Stones – NEJM Resident 360
Guideline | Diagnosis, management, and follow-up of the incidentally discovered adrenal mass
6 Mar, 2023 | 14:16h | UTC
Perspective | Gender dysphoria in young people is rising — and so is professional disagreement
28 Feb, 2023 | 13:55h | UTCGender dysphoria in young people is rising—and so is professional disagreement – The BMJ
News Release: Gender dysphoria is rising—and so is professional disagreement – BMJ Newsroom
Commentary on Twitter
More children and adolescents are identifying as transgender and are being offered medical treatment, especially in the US—but some providers and European authorities are urging caution because of a lack of strong evidence. @writingblock reports https://t.co/24aDMo7rb0
— The BMJ (@bmj_latest) February 26, 2023
RCT | Adjuvant nivolumab plus ipilimumab not better than placebo for localized renal cell carcinoma after nephrectomy
16 Feb, 2023 | 15:15h | UTCAdjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
USPSTF reaffirms recommendation against serologic screening for genital herpes infection
15 Feb, 2023 | 16:17h | UTCSummary: The US Preventive Services Task Force (USPSTF) recommends against routine screening for genital herpes infection in asymptomatic adolescents, adults, and pregnant women, as the potential harms of such screening outweigh the benefits. This recommendation is based on a systematic evaluation of the available evidence, and the USPSTF has moderate certainty in its conclusion.*
Evidence Report: Serologic Screening for Genital Herpes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Reducing HSV-2 Morbidity and MortalityRoutine Serologic Screening Still Not the Best Answer – JAMA
Reaffirmed USPSTF Recommendation Against Serologic Screening for Genital Herpes: Empowering Clinicians and Reducing Potential Harm – JAMA Dermatology (free for a limited period)
Author Interview: Serologic Screening for Genital Herpes Infection – JAMA
JAMA Patient Page: Screening for Genital Herpes
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
RCT | Antimicrobial therapy for 7 days is inferior to treatment for 14 days in men with febrile urinary tract infection
15 Feb, 2023 | 16:11h | UTCSummary: This study aimed to compare the effectiveness of 7-day versus 14-day antibiotic treatment for febrile urinary tract infections in men. The multicenter randomized, double-blind, placebo-controlled non-inferiority trial enrolled 282 men from 27 centers in France. The primary endpoint was treatment success, defined as a negative urine culture, the absence of fever, and no subsequent antibiotic treatment between the end of treatment and 6 weeks after day 1. The results showed that the 14-day treatment was superior to the 7-day treatment, with a treatment success rate of 77.6% versus 55.7%, respectively. Adverse events were similar in both groups, and rectal carriage of resistant Enterobacterales did not differ. Therefore, the study concludes that treatment with ofloxacin for 7 days is inferior to 14 days for febrile UTI in men and should not be recommended.*
Article: Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double blind placebo-controlled, randomized clinical trial – Clinical Infectious Diseases (link to abstract – $ for full-text)
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
RCT | Hyaluronic acid spacer for hypofractionated prostate radiation therapy
13 Feb, 2023 | 12:25h | UTC
Commentary on Twitter
Multicenter randomized clin trial in prostate cancer tested presence or absence of hyaluronic acid rectal spacer before receiving hypofractionated radiation, showed acute grade >2 GI toxicity in 2.9% of pts w/spacer vs. 13.8% in control group #PCSM #RadOnc https://t.co/eTifx0b1x2
— JAMA Oncology (@JAMAOnc) February 9, 2023
Consensus Statement | Development of an Enhanced Recovery After Surgery (ERAS) surgical safety checklist
10 Feb, 2023 | 14:03h | UTC
Commentary from the author on Twitter (thread – click for more)
The @WHO Surgical Safety Checklist and the @ErasSociety guidelines come together.🔥
#ERAS teams can leverage 2 tools in 1 to improve care in critical perioperative communication moments https://t.co/EaXYyj7b56
via @JAMANetworkOpen part of @JAMANetwork pic.twitter.com/WHJMjThubO— Mary Brindle (@MaryEBrindle) February 8, 2023
RCT | Machine perfusion is superior to therapeutic hypothermia for reducing delayed graft function after kidney transplantation
6 Feb, 2023 | 13:28h | UTCHypothermia or Machine Perfusion in Kidney Donors – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Machine Perfusion of Kidneys Protects Against Delayed Graft Function – HealthDay
Commentary with video on Twitter
Hypothermia of brain-dead kidney donors and machine perfusion of the kidney can reduce delayed graft function, but whether hypothermia is as effective as machine perfusion is unclear. New research findings are summarized in a short video. https://t.co/mL0YQZYoK1 pic.twitter.com/ANnJl27mkl
— NEJM (@NEJM) February 4, 2023
Syphilis in dermatology: recognition and management
31 Jan, 2023 | 14:01h | UTCSyphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology (if the link is paywalled, try this one in PMC)
Guideline | Management of adult renal trauma
30 Jan, 2023 | 01:20h | UTCRelated:
Kidney and uro-trauma: WSES-AAST guidelines – World Journal of Emergency Surgery
Urotrauma: AUA Guideline – The Journal of Urology
Urological Trauma – European Association of Urology
Renal trauma: the current best practice – Therapeutic Advances in Urology
Guideline | Management of metastatic castration-naive and castration-sensitive prostate cancer
23 Jan, 2023 | 13:33h | UTC2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF here)
See also: Summary of changes (PDF here)
M-A | Routine use of α1-antagonists in orthopedic surgery increases adverse events and does not reduce postoperative urinary retention
23 Jan, 2023 | 13:20h | UTC
Commentary on Twitter
#ICYMI
Do α1-antagonists prevent retention after #ortho #surgery?#systematicreview and meta-analysis says no, and high rates of α related complications seencaveat – few trials!https://t.co/kTaK5Oej85#some4surgery @asgbi @SEIQuirurgica pic.twitter.com/amMrVRGhbf
— BJS Open (@BjsOpen) January 19, 2023
Guidelines | Enhanced recovery after surgery recommendations for renal transplantation
20 Jan, 2023 | 14:51h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Commentary on Twitter
Free to access in January's BJS: Enhanced recovery after surgery recommendations for renal transplantation: guidelines https://t.co/VkTRQmDWRS @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @paulo_sutt @robhinchliffe1 @young_bjs pic.twitter.com/7JQYrlZJnO
— BJS (@BJSurgery) December 30, 2022
CanRisk-Prostate | A comprehensive, externally validated risk model for the prediction of future prostate cancer
20 Jan, 2023 | 14:22h | UTCCommentary: Risk Model for Predicting the Development of Prostate Cancer – The ASCO Post
News Release: Prostate cancer risk prediction algorithm could help target testing at men at greatest risk – University of Cambridge
Metomidate PET-CT vs. adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial
19 Jan, 2023 | 14:19h | UTCNews Release: Ten-minute scan enables detection and cure of the commonest cause of high blood pressure – Queen Mary University of London